Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[From stiff man syndrome to stiff person spectrum disorders].

Der Nervenarzt·2018

Same author

[Myoclonus as a movement disorder].

Der Nervenarzt·2017

Same author

Clinical Muscle Testing Compared with Whole-Body Magnetic Resonance Imaging in Facio-scapulo-humeral Muscular Dystrophy.

Clinical neuroradiology·2015

Same author

Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes.

Brain : a journal of neurology·2014

Same author

Comparative analysis of the susceptibility to triclosan and three other biocides of avian Salmonella enterica isolates collected 1979 through 1994 and 2004 through 2010.

Journal of food protection·2013

Same author

[Stiff man syndrome and variants].

Der Nervenarzt·2013

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

[Intravenous immunoglobulins in multiple sclerosis. An update].

S Schwarz¹, H-M Meinck, B Storch-Hagenlocher

¹Zentralinstitut für Seelische Gesundheit, Klinikum Mannheim, Neurologische Universitätsklinik, Universität Heidelberg, Quadrat J 5, 68159 Mannheim. st_schwarz@hotmail.com

|August 8, 2009

Summary

Intravenous immunoglobulins (IVIG) show potential as a safe second-line treatment for relapsing-remitting MS. However, conclusive evidence on IVIG efficacy and optimal dosage remains limited.

More Related Videos

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

Related Experiment Videos

Last Updated: Jun 21, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

Area of Science:

Neurology
Immunology
Pharmacology

Context:

Multiple Sclerosis (MS) management often requires alternative therapies when standard treatments fail or are contraindicated.
Intravenous immunoglobulins (IVIG) are increasingly considered for MS patients, particularly those with relapsing-remitting MS (RRMS).
Existing immunomodulatory drugs may not be suitable for all MS patients, especially during pregnancy and postpartum.

Purpose:

To evaluate the safety and efficacy of intravenous immunoglobulins (IVIG) as a treatment option for Multiple Sclerosis (MS).
To review current clinical evidence supporting IVIG use in various MS patient populations.
To identify gaps in knowledge regarding IVIG's long-term effects and optimal dosing in MS.

Summary:

Clinical studies suggest IVIG is generally safe and well-tolerated in MS patients, with rare serious side effects.
While some research indicates potential benefits of IVIG for relapsing-remitting MS (RRMS), recent studies like PRIVIG have not demonstrated clinical efficacy.
Limited data exists for IVIG use in MS during pregnancy and postpartum, and efficacy for other MS indications is largely unproven or negative.

Impact:

IVIG may serve as a viable second-line treatment for RRMS patients unresponsive to other therapies.
Further research is crucial to establish definitive efficacy, long-term outcomes, and appropriate dosing strategies for IVIG in MS.
The findings highlight the need for more robust clinical trials to support IVIG's role in comprehensive MS care.